公开(公告)号：JP2004196821A

公开(公告)日：2004-07-15

申请号：JP2004065900

申请日：2004-03-09

Applicant: Sepracor Inc ,  セプラコール・インコーポレイテッドSepracor, Inc.

Inventor： MORLEY JOHN

IPC: C07D215/26 ,  A61K31/135 ,  A61K31/137 ,  A61K31/167 ,  A61K31/17 ,  A61K31/235 ,  A61K31/24 ,  A61K31/27 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/52 ,  A61K31/522 ,  A61K45/00 ,  A61P11/00 ,  A61P11/08 ,  A61P25/02 ,  A61P29/00 ,  C07D211/22 ,  C07D213/65 ,  C07D473/08

CPC classification number: A61K31/52 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/17 ,  A61K31/235 ,  A61K31/27 ,  A61K31/44 ,  A61K31/445 ,  A61K31/47 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To reduce occurrence of side effects in a medicinal composition comprising a beta-2-bronchodilator drug as a principal component having a partial chemical structure expressed by the formula of R
1 -CH(OH)-CHR
2 -NR
3 - [in the formula R
1 is an aromatic ring, R
2 is H or a lower alkyl group, R
3 is H or a lower alkyl group by combining with R
2 ], for improving treatment to obstructive or inflammatory airways diseases.
SOLUTION: The medicinal composition comprises as the active ingredient i.e., the selective β2-sympathomimetic bronchodilator, ≥95% of R- or R, R-enantiomer.
COPYRIGHT: (C)2004,JPO&NCIPI

公开(公告)号：JP2008019281A

公开(公告)日：2008-01-31

申请号：JP2007264563

申请日：2007-10-10

Applicant: Sepracor Inc ,  セプラコール・インコーポレイテッドSepracor Inc.

Inventor： MORLEY JOHN

IPC: A61K31/137 ,  C07D215/26 ,  A61K31/135 ,  A61K31/167 ,  A61K31/17 ,  A61K31/235 ,  A61K31/24 ,  A61K31/27 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/52 ,  A61K31/522 ,  A61K45/00 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P25/02 ,  A61P29/00 ,  A61P43/00 ,  C07D211/22 ,  C07D213/65 ,  C07D473/08

CPC classification number: A61K31/52 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/17 ,  A61K31/235 ,  A61K31/27 ,  A61K31/44 ,  A61K31/445 ,  A61K31/47 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To reduce side effects of a medicinal composition for improving treatment of inflammatory or obstructive airways diseases, comprising as an active ingredient a β-2-bronchodilator having a group expressed by the partial formula: R 1 -CH(OH)-CHR 2 -NR 3 - [wherein, R 1 is an aromatic ring; R 2 is H or a lower alkyl; R 3 is H or a lower alkyl obtained by combining with R 2 ] in the chemical structure thereof. SOLUTION: As the selective β-2-sympathomimetic bronchodilator of the active ingredient, one comprising R- or R, R-enantiomer of ≥95% is used. COPYRIGHT: (C)2008,JPO&INPIT

Abstract translation: 解决问题：为了减少用于改善炎性或阻塞性气道疾病的治疗的药物组合物的副作用，其包含作为活性成分的具有由下式表示的基团的β-2-支气管扩张剂：R SB < 1 -CH（OH）-CHR SB 2 - 其中R 1是芳环; R SB 2是H或低级烷基; R 3是在其化学结构中通过与R SB 2结合而获得的H或H或低级烷基。 解决方案：作为活性成分的选择性β-2-拟交感神经支气管扩张剂，使用含有≥95％的R-或R，R-对映异构体的那些。 版权所有（C）2008，JPO＆INPIT

公开(公告)号：JP4328021B2

公开(公告)日：2009-09-09

申请号：JP2000555854

申请日：1999-06-22

Applicant: セプレイサー インコーポレイテッドSepracor Inc.

Inventor： ヒュー セナナヤケ，クリス

IPC: A61P11/08 ,  C07C215/78 ,  A61K31/137 ,  C07B61/00 ,  C07C213/02 ,  C07C213/04 ,  C07C217/60 ,  C07C217/70

CPC classification number: C07C213/04 ,  C07B2200/07 ,  C07C217/60 ,  C07C217/70

公开(公告)号：JP2002308772A

公开(公告)日：2002-10-23

申请号：JP2002054838

申请日：2002-02-28

Applicant: SEPRACOR INC

Inventor： WOOSLEY RAYMOND L ,  ABERG A K GUNNAR

IPC: C07D401/12 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/454 ,  A61K45/00 ,  A61K45/06 ,  A61P3/08 ,  A61P3/10 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P31/12 ,  A61P37/08 ,  A61P43/00

Abstract: PROBLEM TO BE SOLVED: To provide an antihistaminic agent for treating an allergic disease without inducing significant cardiac arrhythmia in a human patient. SOLUTION: A method for using a composition containing norastemizole or its pharmaceutically permissible salt for manufacturing a pharmaceutical agent to be used in antihistaminic treatment without inducing significant cardiac arrhythmia.

公开(公告)号：JPH05186339A

公开(公告)日：1993-07-27

申请号：JP31704791

申请日：1991-11-29

Applicant: SEPRACOR INC

Inventor： JIEEMUSU DABURIYUU YANGU ,  SUTEIIBUN BURANDO

IPC: A61K31/02 ,  A61K31/08 ,  A61P23/00 ,  A61P25/20 ,  A61P43/00

Abstract: PURPOSE: To diminish adverse effects caused by a high dose of racemic mixture of isoflurane or desflurane which is an anesthetic for inducing and maintaining anesthesia and which is administered by inhalation. CONSTITUTION: This method of inducing and maintaining anesthesia comprises administering by inhalation to a warm blooded animal including a mammal in need of anesthesia an amount sufficient to induce and maintain anesthesia but insufficient to cause adverse effects, of (S)-isoflurane or (S)-desflurane substantially not containing (R)-stereoisomer, while diminishing the concomitant liability of adverse effects, such as hypoventilation, low blood pressure and arrhythmia, associated with the administration. The inhalation concentration of the anesthetic (S-isomer) administered for inducing the anesthesia is 0.5-5.0%, 0.5-2.5%, when nitrous oxide is simultaneously administered, or 0.5-3.5%, when oxygen is simultaneously administered. Since the (S)-isoflurane or (S)-desflurane exhibits the anesthetic activity in a lower concentration and at a lower dose than the corresponding racemic mixture, adverse effects are little.

公开(公告)号：JP2008019281A6

公开(公告)日：2008-01-31

申请号：JP2007264563A

申请日：2007-10-10

Applicant: セプラコール・インコーポレイテッドSepracor Inc.

Inventor： ジョン・モーリー

Abstract: 【課題】その化学構造中に部分式：
Ｒ
１ −ＣＨ（ＯＨ）−ＣＨＲ
２ −ＮＲ
３ −
[式中、Ｒ
１は 芳香環基であり、Ｒ
２ は水素または低級アルキル基であり、Ｒ
３ は水素であるか、Ｒ
２ とＲ
３ は一緒になって低級アルキレン基を表わす。 ]で表される基を有するベータ−２−気管支拡張薬を有効成分とする炎症性または閉塞性気道疾患の処置の改善用の医薬組成物における副作用を抑制すること。
【解決手段】有効成分である選択的ベータ−２−交感神経作用性気管支拡張薬として、そのＲ−またはＲ、Ｒ−エナンチオマー９５％以上含有するものを使用すること。
【選択図】なし

公开(公告)号：JP2006509802A

公开(公告)日：2006-03-23

申请号：JP2004559144

申请日：2003-12-08

Applicant: セプラコール・インコーポレイテッドSepracor, Inc.

Inventor： クレイグ・スタージ ,  ポール・マッグリン ,  ロジャー・バケイル

IPC: A61K31/137 ,  A61K9/14 ,  A61K9/72 ,  A61K31/205 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61L9/04 ,  A61M13/00 ,  A61M15/00 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  C07C213/02 ,  C07C213/10 ,  C07C215/60

CPC classification number: C07C215/60 ,  A61K9/008 ,  A61K9/14 ,  A61K31/205 ,  A61M15/002 ,  A61M15/009 ,  A61M2202/0484 ,  A61M2202/0488 ,  A61M2202/064 ,  C07B2200/07 ,  C07B2200/13 ,  C07C59/255 ,  C09K3/30

Abstract: レバルブテロール Ｌ−酒石酸塩より、定用量吸入器に使用するのに望ましい性質を有する結晶が得られた。

Abstract translation: 适用于使用计量吸入器给药的左沙利度胺的气溶胶制剂可以从左美沙芬醇L-酒石酸晶体制备，其可以通过将莱瓦列特与L-酒石酸溶液组合而获得。

公开(公告)号：JP2002255817A

公开(公告)日：2002-09-11

申请号：JP2002054842

申请日：2002-02-28

Applicant: SEPRACOR INC

Inventor： WOOSLEY RAYMOND L ,  ABERG A K GUNNAR

IPC: C07D401/12 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/454 ,  A61K45/00 ,  A61K45/06 ,  A61P3/08 ,  A61P3/10 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P31/12 ,  A61P37/08 ,  A61P43/00

Abstract: PROBLEM TO BE SOLVED: To obtain an antihistaminic agent for treating allergic diseases without inducing any significant cardiac arrhythmia in human patients. SOLUTION: This method is to use a composition comprising norastemizole or its pharmaceutically acceptable salt for producing medicines used in anti- histaminic treatment avoiding the significant cardiac arrhythmia.

公开(公告)号：JP2000086514A

公开(公告)日：2000-03-28

申请号：JP29122399

申请日：1999-10-13

Applicant: SEPRACOR INC ,  UNIV GEORGETOWN

Inventor： YOUNG JAMES W ,  WOOSLEY RAYMOND L ,  GRAY NANCY M ,  CHEN YIWANG

IPC: C07D211/22 ,  A61K9/48 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/60 ,  A61K45/00 ,  A61K45/06 ,  A61P17/00 ,  A61P27/16 ,  A61P37/08 ,  A61P43/00

Abstract: PROBLEM TO BE SOLVED: To obtain the subject composition capable of avoiding cardiovascular system side effects caused by the administration of terfenadine by adding a terfenadine carboxylate and a non-steroidal anti-inflammatory medicine or non-narcotic analgesic medicine. SOLUTION: This medicinal composition contains (A) a terfenadine carboxylate 4-[1-hydroxy-4-(4-hydroxydiphenylmethyl-1-piperidinyl)butyl]-α,α- dimethylbenzene acetate, 1[p-(2-hydroxymethylprop-2-yl-phenyl]-4-[4-(α-hydroxy-α- phenylbenzyl)piperidin-1-yl]butanol, etc.}, of the formula (Z is COOH, COOCH3, etc.), which is a metabolic derivative of the terfenadine, and (B) a non-steroidal anti-inflammatory medicine or a non-narcotic analgesic medicine (for example, acetylsalicylate, ibuprofen). The component A and the component B are preferably contained in amounts of 20-200 mg and 25-600 mg, respectively.

公开(公告)号：JP2559386B2

公开(公告)日：1996-12-04

申请号：JP50547686

申请日：1986-10-08

Applicant: SEPRACOR INC

Inventor： MATOSON SUTEIIFUN ERU

IPC: B01D61/00 ,  B01D69/14 ,  B01J19/24 ,  B01J35/02 ,  C12M1/12 ,  C12M1/40 ,  C12N11/02